Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
AcromegalyNeuroendocrine Tumors
Interventions
DRUG

octreotide FluidCrystal® injection depot

Trial Locations (10)

Unknown

Hospices Civils de Lyon, Bron

CHU Rouen, Hôpital Charles Nicolle, Rouen

Abteilung: Klinische Studien, Bad Berka

Charité Campus Virchow Klinikum, Berlin

Universitätsklinikum Essen, Essen

RCCS Azienda Ospedaliera Universitaria San Martino IST, Genova

Fondazione Irccs Ca' Granda, Milan

Università degli Studi di Napoli Federico II, Napoli

Istituto Clinico Humanitas, Rozzano

Akademiska sjukhuset, Uppsala

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Camurus AB

INDUSTRY